title: Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey.
abstract: Giant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54 × 40 × 40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17 × 12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment.
authors: Department of Endocrinology and Metabolism, Bezmialem Vakıf University, Istanbul, Turkey.
authors: Ertugrul
authors: E
authors: Tasan
authors: Department of Neurosurgery, Bezmialem Vakıf University, Istanbul, Turkey.
authors: Hakan
authors: H
authors: Hanimoglu
authors: Department of Internal Medicine, Bezmialem Vakif University, Istanbul, Turkey.
authors: Seda
authors: S
authors: Turgut
authors: Department of Endocrinology and Metabolism, Bezmialem Vakıf University, Istanbul, Turkey.
authors: Mahmut Muzaffer
authors: MM
authors: Ilhan
authors: Department of Neurosurgery, Bezmialem Vakıf University, Istanbul, Turkey.
authors: Sevket
authors: S
authors: Evran
authors: Department of Neurosurgery, Bezmialem Vakıf University, Istanbul, Turkey.
authors: Mehmet Yasar
authors: MY
authors: Kaynar
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000077465:Cabergoline; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009897:Optic Chiasm / Q000473:pathology; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D015175:Prolactinoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D015354:Vision, Low / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D000970:Antineoplastic Agents; D004873:Ergolines; D000077465:Cabergoline